Carissa Cruz Berrios
Pulmonary Disease · Caguas, PRNPI 1366631665
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AstraZeneca at 37.7% of the total.
Across 164 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$872
- Boehringer Ingelheim$359
- E.r. Squibb & Sons, L.L.C.$225
- Amgen$160
- Mylan Specialty L.p.$128
- plus $519 from 6 others
What the payments were for
- Food & beverage$3,59799%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 70 | $1,368 |
| GSK | 44 | $872 |
| Boehringer Ingelheim | 16 | $359 |
| E.r. Squibb & Sons, L.L.C. | 2 | $225 |
| Amgen | 7 | $160 |
| Mylan Specialty L.p. | 6 | $128 |
| Eli Lilly Export S.A. Puerto Rico Branch | 5 | $119 |
| Johnson & Johnson | 2 | $111 |
| Sanofi | 4 | $97 |
| Viatris Specialty LLC | 3 | $78 |
| Genentech USA, Inc. | 3 | $72 |
| Merck | 2 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$225
How this compares
$3,631 in reported general payments places this provider in the 65th percentile of 138 pulmonary disease providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 2,144 | $892,065 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 780 | $522,770 |
| Fasenra PenBenralizumab | 26 | $151,851 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 3,327 | $143,775 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 190 | $124,445 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 1,247 | $122,094 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 364 | $82,203 |
| Spiriva RespimatTiotropium Bromide | 111 | $59,243 |
| Wixela InhubFluticasone Propion/Salmeterol | 217 | $40,400 |
| SymbicortBudesonide/Formoterol Fumarate | 178 | $38,633 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 486 | $30,756 |
| Azelastine Hcl | 685 | $15,150 |
| Fluticasone Propionate | 768 | $13,033 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $7,314 |
| Famotidine | 998 | $5,602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $872 | $1,418,2542,936 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,368 | $163,078368 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $359 | $66,558126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 138 pulmonary disease providers in Puerto Rico.
Other pulmonary disease in Caguas
- Arnulfo Santana SantanaCaguas$6K
- Rosangela Fernandez MederoCaguas$5K
- Juan Garcia PueblaCaguas$5K
- Jose Valles QuinonesCaguas$3K
- Alvaro Aranda RodriguezGuaynabo$725K
- Luis Garcia BarretoCoamo$393K
- Luis Nieves GarrasteguiRio Piedras$121K
- Jahaira Serrano DominguezArecibo$102K
- William Villanueva-BosqueArecibo$67K
- Domingo Chardon FelicianoPonce$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.